de Brito E Cunha Danielle, Frederico Ana Beatriz Teixeira, Azamor Tamiris, Melgaço Juliana Gil, da Costa Neves Patricia Cristina, Bom Ana Paula Dinis Ano, Tilli Tatiana Martins, Missailidis Sotiris
Immunological Technology Laboratory, Institute of Technology in Immunobiologicals, Bio-Manguinhos, Oswaldo Cruz Foundation, Fiocruz, Rio de Janeiro 21040-900, Brazil.
Translational Oncology Platform, Center for Technological Development in Health, Oswaldo Cruz Foundation, Fiocruz, Rio de Janeiro 21040-900, Brazil.
Pharmaceuticals (Basel). 2022 May 5;15(5):575. doi: 10.3390/ph15050575.
The depth and versatility of siRNA technologies enable their use in disease targets that are undruggable by small molecules or that seek to achieve a refined turn-off of the genes for any therapeutic area. Major extracellular barriers are enzymatic degradation of siRNAs by serum endonucleases and RNAases, renal clearance of the siRNA delivery system, the impermeability of biological membranes for siRNA, activation of the immune system, plasma protein sequestration, and capillary endothelium crossing. To overcome the intrinsic difficulties of the use of siRNA molecules, therapeutic applications require nanometric delivery carriers aiming to protect double-strands and deliver molecules to target cells. This review discusses the history of siRNAs, siRNA design, and delivery strategies, with a focus on progress made regarding siRNA molecules in clinical trials and how siRNA has become a valuable asset for biopharmaceutical companies.
小干扰RNA(siRNA)技术的深度和多功能性使其能够用于小分子无法作用的疾病靶点,或旨在对任何治疗领域的基因实现精确关闭的靶点。主要的细胞外障碍包括血清核酸内切酶和RNA酶对siRNA的酶促降解、siRNA递送系统的肾脏清除、生物膜对siRNA的不透性、免疫系统的激活、血浆蛋白隔离以及穿过毛细血管内皮。为了克服使用siRNA分子的内在困难,治疗应用需要纳米级递送载体,旨在保护双链并将分子递送至靶细胞。本文综述了siRNA的历史、siRNA设计和递送策略,重点讨论了siRNA分子在临床试验中取得的进展以及siRNA如何成为生物制药公司的宝贵资产。